ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Sold by Marshall Wace LLP

Marshall Wace LLP lowered its position in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 95.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,853 shares of the company's stock after selling 263,779 shares during the period. Marshall Wace LLP's holdings in ClearPoint Neuro were worth $198,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the stock. NewEdge Advisors LLC increased its position in shares of ClearPoint Neuro by 7.3% during the fourth quarter. NewEdge Advisors LLC now owns 21,114 shares of the company's stock worth $325,000 after acquiring an additional 1,431 shares during the period. Barclays PLC increased its holdings in ClearPoint Neuro by 1,070.9% during the fourth quarter. Barclays PLC now owns 66,436 shares of the company's stock valued at $1,022,000 after buying an additional 60,762 shares during the period. Invesco Ltd. purchased a new position in ClearPoint Neuro during the fourth quarter valued at approximately $3,814,000. ExodusPoint Capital Management LP purchased a new position in ClearPoint Neuro during the fourth quarter valued at approximately $204,000. Finally, Trexquant Investment LP increased its holdings in ClearPoint Neuro by 10.3% during the fourth quarter. Trexquant Investment LP now owns 78,362 shares of the company's stock valued at $1,205,000 after buying an additional 7,290 shares during the period. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Price Performance

NASDAQ CLPT traded down $0.07 on Friday, hitting $14.18. The stock had a trading volume of 199,598 shares, compared to its average volume of 228,039. The business's fifty day moving average price is $12.85 and its 200 day moving average price is $14.23. ClearPoint Neuro, Inc. has a 52-week low of $5.11 and a 52-week high of $19.22. The stock has a market cap of $396.76 million, a price-to-earnings ratio of -20.55 and a beta of 1.03.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. The firm had revenue of $7.77 million during the quarter, compared to analysts' expectations of $8.23 million. As a group, sell-side analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Stifel Nicolaus lifted their price objective on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. B. Riley lifted their price objective on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Finally, Lake Street Capital lifted their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a "buy" rating in a report on Tuesday, January 21st.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.